Shonali Midha

12PUBLICATIONS
92CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Mar 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Oct 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Clifton C Mo, Yuxin Liu, Omar Nadeem

|Aug 08, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Feb 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Doris K Hansen, Lauren C Peres, Danai Dima

Pageof 2

Frequent Collaborators

6 joint publications

Aimaz Afrough

6 joint publications

Doris K Hansen

6 joint publications

Adam S Sperling

6 joint publications

Surbhi Sidana